These products, which are based on well-known injectable drugs are designed to enhance patient safety, compliance and comfort. CROSSJECT develops a product portfolio that combines well-known drugs with an innovative mode of injection. It is particularly well suited to emergency situation and most chronic treatments, and can be adapted to a wide range of specific situations.
CROSSJECT’s pre-filled and single-use ZENEO® injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that the ZENEO® platform can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. ZENEO® is the result of € 60M of investments through 12 years of R&D and is protected by more than 400 patents. It already exists under its industrial form and was subject to 8 clinical studies including TNF mabs (for preclinical studies) and vaccines.